This is a fictional, illustrative case created for education. It is not medical advice, diagnosis, or treatment, and does not describe a real person.

The best treatment helped. Her skin still would not heal.

Aisha, 29, finally found a treatment that helped her eczema. Dupilumab cut flares by about 60%, but the dryness, itch, and hand/eye flares kept returning. Her results showed what the medication could not fix.

Persona

Aisha, 29, Female, British-Somali, Pharmacist.

Aisha has had eczema since age 3. Over 26 years she tried topical steroids, emollients, dairy-free, egg-free, and gluten-free diets. Eight months ago she started dupilumab, and for the first time something clearly helped. Flares dropped by about 60%. But the background dryness, itch, and flares around her eyes and hands remain. As a pharmacist, she understands the medication. She wants to know why the best treatment left so much behind.

Family history: Mother: asthma. Brother: hay fever and eczema. Father: psoriasis. Classic atopic triad — strong family signal for type 2 inflammatory predisposition.

Clinical picture

Symptoms

Labs

Medications

Supplements

Lifestyle

Genetics

The first treatment that helped still left a mystery

Aisha has lived with eczema since she was three. She has tried mild, moderate, and potent topical steroids. She has tried countless emollients and long diet exclusions. Nothing lasted. When her dermatologist offered dupilumab, she understood the mechanism because she dispenses it as a pharmacist. She tried it, and for the first time in adulthood, her eczema clearly improved. Flares dropped by about 60%. But her skin never fully calmed. The itch returned. Her hands and eyelids still flared. The question became sharper: what was dupilumab helping, and what was it leaving untouched?

The fire was lower, but the wall was still broken

Eczema can be driven by immune overactivity, a weak skin barrier, or both. Dupilumab targets the immune side, and for Aisha it clearly works. But if the outer skin layer is physically leaky, allergens, irritants, and microbes keep getting through. The immune fire gets quieter, but the wall still has gaps. That is the part her remaining symptoms point to: not a failed biologic, but an untreated barrier problem.

Two barrier problems were hiding under the inflammation

Aisha carries two different loss-of-function FLG variants, meaning the filaggrin protein that helps build the outer skin layer is absent rather than simply low. Her water-loss test shows the effect: moisture is escaping at nearly three times the threshold for a compromised barrier. SPINK5 adds a second problem. Even when her skin tries to repair, enzymes can break that repair down too quickly. Dupilumab can calm inflammation, but it cannot rebuild a missing structural protein. That is why barrier repair needs to be a central treatment, not an afterthought.

The medicine fit. The repair signal was still low.

Aisha's IL-13 result explains why dupilumab helped: it blocks a signal she tends to overproduce. But calming that signal does not erase the FLG and SPINK5 barrier defects. A second issue is vitamin D. Her level is low, and her VDR result suggests her cells may need a stronger vitamin D signal to respond. Vitamin D helps turn on skin-barrier repair genes, including pathways already under strain in her profile. For Aisha, correcting vitamin D is not a generic wellness step. It supports the repair system her skin is trying to use.

What targets the part dupilumab cannot reach

Why 40% of Aisha's eczema survives dupilumab — and what addresses it

Dupilumab targets the immune response, and it works. The remaining burden points to barrier defects and nutrient gaps that the biologic does not repair directly. Residual eczema on dupilumab — barrier defect untreated baseline 40%.